# SeLux Diagnostics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/selux-diagnostics

- Industry: Biotechnology
- Headquarters: US
- Website: www.seluxdx.com
- Total disclosed funding: $72M
- Latest round: Series C (Feb 11, 2022)
- Investors on record: 4

## About

Founded in 2014 and based in Massachusetts, US, SeLux Diagnostics, Inc. develops a phenotyping platform for treating infectious diseases. As of 2024, the company is headed by its CEO Steve Lufkin. The company was co-founded by Eric Stern and Aleksandar Vacic. In April 2024, the firm raised USD 48 million in venture funding led by returning investor RA Capital Management, with participation from other returning investors Northpond Ventures, Sands Capital Ventures, and Schooner Capital.

Selux Diagnostics' product is the Selux NGP System which provides automated aminotransferase (AST) results and personalized therapy results for all patients suffering from infectious disease. Diagnostic results are delivered by this technique in the same shift as positive blood cultures. Comprehensive testing for all sample types and antibiotics is offered by the Selux NGP System.

The company plans to use the April 2024 funding to support its commercialization across the United States.

## Funding rounds

- Series C, Feb 11, 2022, $48M — RA Capital Management, Schooner Capital, Sands Capital Alternatives, Northpond Ventures
- Series B, Mar 28, 2018, $24M — RA Capital Management, Schooner Capital, Sands Capital Alternatives, Northpond Ventures

## Investors

- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series B, Series C
- Schooner Capital (https://capitalatlas.ai/funds/schooner-capital) — Series B, Series C
- Sands Capital Alternatives (https://capitalatlas.ai/funds/sands-capital-alternatives) — Series B, Series C
- Northpond Ventures (https://capitalatlas.ai/funds/northpond-ventures) — Series B, Series C